Jeffrey A. Stafford

3.5k total citations
43 papers, 2.3k citations indexed

About

Jeffrey A. Stafford is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Jeffrey A. Stafford has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 16 papers in Organic Chemistry and 9 papers in Oncology. Recurrent topics in Jeffrey A. Stafford's work include Epigenetics and DNA Methylation (9 papers), Histone Deacetylase Inhibitors Research (7 papers) and Angiogenesis and VEGF in Cancer (6 papers). Jeffrey A. Stafford is often cited by papers focused on Epigenetics and DNA Methylation (9 papers), Histone Deacetylase Inhibitors Research (7 papers) and Angiogenesis and VEGF in Cancer (6 papers). Jeffrey A. Stafford collaborates with scholars based in United States, Japan and Germany. Jeffrey A. Stafford's co-authors include Clayton H. Heathcock, Mui Cheung, Paul L. Feldman, Lihong Shi, Amogh Boloor, Michael B. Wallace, David L. Clark, Stephen W. Kaldor, Rakesh Kumar and Andrea H. Epperly and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer Research.

In The Last Decade

Jeffrey A. Stafford

43 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey A. Stafford United States 23 956 786 547 305 268 43 2.3k
Toichi Takenaka Japan 25 781 0.8× 237 0.3× 60 0.1× 176 0.6× 210 0.8× 106 1.8k
Xueyan Wang China 16 679 0.7× 252 0.3× 342 0.6× 105 0.3× 219 0.8× 42 1.5k
Cai Li China 18 475 0.5× 154 0.2× 386 0.7× 316 1.0× 61 0.2× 61 1.4k
Simon Joel United Kingdom 19 652 0.7× 42 0.1× 359 0.7× 37 0.1× 95 0.4× 36 1.7k
Ryuichi Nishii Japan 24 439 0.5× 80 0.1× 293 0.5× 137 0.4× 386 1.4× 132 1.8k
Peter S. Chan United States 19 690 0.7× 342 0.4× 90 0.2× 59 0.2× 280 1.0× 53 1.5k
George J. Eiermann United States 22 561 0.6× 215 0.3× 375 0.7× 660 2.2× 50 0.2× 30 1.4k
Suzanne Moreland United States 29 1.1k 1.2× 2.3k 2.9× 54 0.1× 119 0.4× 101 0.4× 76 3.8k
Raymond F. Kauffman United States 24 1.0k 1.1× 277 0.4× 305 0.6× 512 1.7× 53 0.2× 47 2.2k
Cornelia Weber Germany 18 307 0.3× 106 0.1× 127 0.2× 90 0.3× 376 1.4× 46 1.3k

Countries citing papers authored by Jeffrey A. Stafford

Since Specialization
Citations

This map shows the geographic impact of Jeffrey A. Stafford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Stafford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Stafford more than expected).

Fields of papers citing papers by Jeffrey A. Stafford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Stafford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Stafford. The network helps show where Jeffrey A. Stafford may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Stafford

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Stafford. A scholar is included among the top collaborators of Jeffrey A. Stafford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Stafford. Jeffrey A. Stafford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takeda, Katsuyuki, Anthony Joetham, Miloš Lazić, et al.. (2023). JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders. Scientific Reports. 13(1). 13524–13524. 14 indexed citations
2.
Chandhasin, Chandtip, Frank Perabo, Young K. Chen, et al.. (2023). TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. Anti-Cancer Drugs. 34(10). 1122–1131. 18 indexed citations
3.
Yoo, Sanghee, Chandtip Chandhasin, Young K. Chen, et al.. (2021). Pharmacologic characterization of TACH101, a first-in-class KDM4 inhibitor for development as a cancer therapeutic.. Journal of Clinical Oncology. 39(15_suppl). e15067–e15067. 1 indexed citations
4.
Nie, Zhe, Lihong Shi, Chon Lai, et al.. (2018). Structure-based design and discovery of potent and selective KDM5 inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(9). 1490–1494. 32 indexed citations
5.
Bennett, Malcolm J., Yiqin Wu, Amogh Boloor, et al.. (2018). Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(10). 1811–1816. 7 indexed citations
6.
Metzger, Eric, Sylvia Urban, Dominica Willmann, et al.. (2017). KDM4 Inhibition Targets Breast Cancer Stem–like Cells. Cancer Research. 77(21). 5900–5912. 73 indexed citations
7.
Kiryanov, Andre A., Christopher M. McBride, Victoria A. Feher, et al.. (2016). Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(5). 1311–1315. 13 indexed citations
8.
Kumar, Rakesh, Victoria B. Knick, Sharon K. Rudolph, et al.. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics. 6(7). 2012–2021. 423 indexed citations
9.
Kilpatrick, Gavin J., Margaret McIntyre, Richard F. Cox, et al.. (2007). CNS 7056. Anesthesiology. 107(1). 60–66. 248 indexed citations
10.
Feng, Jun, Zhiyuan Zhang, Michael B. Wallace, et al.. (2007). Discovery of Alogliptin:  A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV. Journal of Medicinal Chemistry. 50(10). 2297–2300. 326 indexed citations
11.
Veal, James M., Robert T. Nolte, Liping Wang, et al.. (2005). Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 15(15). 3519–3523. 27 indexed citations
12.
Kumar, Rakesh, L.E. Harrington, Teresa M. Hopper, et al.. (2005). Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Journal of Clinical Oncology. 23(16_suppl). 9537–9537. 10 indexed citations
13.
Dev, I K, Ronna E. Dornsife, Teresa M. Hopper, et al.. (2004). Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer. 91(7). 1391–1398. 35 indexed citations
14.
Calvo, Alfonso, Jeffrey A. Stafford, Mui Cheung, et al.. (2004). Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene. 24(5). 790–800. 38 indexed citations
15.
Stafford, Jeffrey A., Gregory J. Pacofsky, Richard F. Cox, et al.. (2002). Identification and Structure–Activity Studies of Novel Ultrashort-Acting Benzodiazepine Receptor Agonists. Bioorganic & Medicinal Chemistry Letters. 12(21). 3215–3218. 24 indexed citations
16.
Brackeen, Marcus F., David J. Cowan, Jeffrey A. Stafford, et al.. (1995). Design and Synthesis of Conformationally Constrained Analogs of 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as Potent Inhibitors of cAMP-Specific Phosphodiesterase. Journal of Medicinal Chemistry. 38(24). 4848–4854. 35 indexed citations
17.
18.
Stafford, Jeffrey A., Paul L. Feldman, David J. Cowan, et al.. (1995). Phosphodiesterase type IV (PDE IV) inhibition. Synthesis and evaluation of a series of 1,3,4-trisubstituted pyrrolidines. Bioorganic & Medicinal Chemistry Letters. 5(17). 1977–1982. 8 indexed citations
19.
Stafford, Jeffrey A.. (1995). Synthesis of (±)-plakoridine A lactam. Tetrahedron Letters. 36(5). 681–682. 5 indexed citations
20.
Feldman, Paul L., Marcus F. Brackeen, David J. Cowan, et al.. (1995). Phosphodiesterase Type IV Inhibition. Structure-Activity Relationships of 1,3-Disubstituted Pyrrolidines. Journal of Medicinal Chemistry. 38(9). 1505–1510. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toichi Takenaka Breakdown of academic impact, for papers by Xueyan Wang Breakdown of academic impact, for papers by Cai Li Breakdown of academic impact, for papers by Simon Joel Breakdown of academic impact, for papers by Ryuichi Nishii Breakdown of academic impact, for papers by Peter S. Chan Breakdown of academic impact, for papers by George J. Eiermann Breakdown of academic impact, for papers by Suzanne Moreland Breakdown of academic impact, for papers by Raymond F. Kauffman Breakdown of academic impact, for papers by Cornelia Weber
Rankless by CCL
2026